Natural history of t(11;14) multiple myeloma

A. Lakshman, M. Alhaj Moustafa, S Vincent Rajkumar, Angela Dispenzieri, Morie Gertz, F. K. Buadi, Martha Lacy, David M Dingli, A. L. Fonder, S. R. Hayman, M. A. Hobbs, Wilson Gonsalves, Y. L. Hwa, Prashant Kapoor, N. Leung, R. S. Go, Yi Lin, Taxiarchis Kourelis, J. A. Lust, Stephen J RussellS. R. Zeldenrust, R. A. Kyle, Shaji K Kumar

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalLeukemia
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Natural history of t(11;14) multiple myeloma'. Together they form a unique fingerprint.

Cite this